FDA 483 - Kolmar Korea Co., Ltd. - Gwanjeong Factory - February 16, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Kolmar Korea Co., Ltd. - Gwanjeong Factory, a drug manufacturer in Sejong-Si, Korea, was cited for multiple significant deficiencies during an FDA inspection from February 8-16, 2024. The observations highlight severe issues across quality control, production record-keeping, data integrity, and raw material warehousing, indicating a lack of robust controls for OTC drug manufacturing. These deficiencies include inadequate microbial testing, missing batch record documentation, insecure computerized lab systems, and a failure to establish impurity specifications.
ID · da79f50f-27f4-4cd8-ba09-eecb69968c47